Bruker Spatial Biology, a division of Bruker Corporation, provides advanced spatial molecular biology solutions, including instruments, assays, software, and services to support life sciences research. By integrating technologies from NanoString and Canopy Biosciences, Bruker offers an extensive portfolio designed to meet the diverse needs of global researchers exploring spatial biology. The CosMx® Spatial Molecular Imager (SMI) enables high-plex detection and analysis of over 6,000 RNAs with single-cell resolution and precise cell segmentation, supported by the cloud-based AtoMx™ Spatial Informatics Platform. The GeoMx® Digital Spatial Profiler is a leading platform for whole-tissue exploration, providing whole transcriptomics and high-plex proteomic readouts. The CellScape™ Precise Spatial Proteomics platform allows for high-plex protein expression analysis at single-cell resolution, using versatile, open-sourced reagents. The nCounter® Analysis System enables rapid quantification of profiling of gene and miRNA expression with high sensitivity. Together, Bruker Spatial Biology’s solutions are supported by a strong team of scientists, sales, and service associates, along with Canopy Multiomic Services for biopharmaceutical research, assay development, and clinical sample testing.
Broad Institute – PRISM Lab
Developed by the Broad Institute of MIT and Harvard, PRISM (Profiling Relative Inhibition Simultaneously in Mixtures) is a novel DNA barcoding technology that allows for rapid, viability screening of more than 900 human cancer cell-line models in mixtures.
Bristol Myers Squibb
Bristol Myers Squibb is a leading global biopharma company focused on discovering, developing and delivering innovative medicines for patients with serious diseases in areas including oncology, hematology, immunology, cardiovascular and neuroscience. Our employees work every day to transform patients’ lives through science. | At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are motivated by the power of science, with a legacy of pursuing bold science across oncology, hematology, cardiovascular, immunology and neuroscience. We’re accelerating the development of new medicines with differentiated research platforms and leading technology to define what’s possible for the future of medicine and the patients we serve.
BostonGene
BostonGene is redefining cancer patient care and drug development through the integration of omnimodal data and AI. Built and validated through an extensive real-world clinical testing network, BostonGene’s foundation model for tumor and immune biology integrates genomic, transcriptomic, and immune data with clinical outcomes to generate biologically grounded, actionable insights. These insights enable biopharma partners design and de-risk trials, identify novel targets, and optimize therapeutic response prediction while improving patient care through clinically integrated innovation.
Boehringer Ingelheim International GmbH
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,300 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at www.boehringer-ingelheim.com.
Boehringer Ingelheim Pharmaceuticals
We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations. Read more here: https://www.boehringer-ingelheim.com/human-health/cancer | Boehringer Ingelheim is working on breakthrough therapies that improve the lives of humans and animals. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. Around 52,000 employees serve more than 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.us | At Boehringer Ingelheim we are driven by the desire to serve humankind by improving human and animal health. As a successful, family owned company we plan in generations. We work together globally and with integrity. Our FOCUS articulates who we are and what we strive for, why we exist, how we work and what we want to achieve.
BLOOMAGE BIOTECHNOLOGY USA INC.
Bloomage (688363. SH) is a global biotechnology and biomaterial company founded in 2000. Driven by synthetic biotechnology, the company is engaged in the development, production and application of bioactive substances that are conducive to life and health, including functional sugars, proteins, polypeptides, amino acids, nucleotides, and natural active compounds. | Bloomage embarked on its journey in 2000, venturing into the production of hyaluronic acid through microbial fermentation. With over two decades of unwavering commitment and ceaseless innovation, Bloomage has established itself as a prominent global biotechnology and biomaterial company that specializes in the industrialization of hyaluronic acid. Bloomage is steadfastly dedicated to enhancing people’s quality of life by creating healthier experiences. Through its pioneering approach, the company strives to unlock the full potential of hyaluronic acid and revolutionize biotechnology.
BioRelo
BioRelo (Biological Relocation Solutions, LLC) is a nationwide lab moving company specializing in the safe, compliant transport and storage of temperature sensitive materials for life science organizations. Our team manages the relocation of biological materials, hazardous chemicals, infectious substances, and cold storage equipment while maintaining strict regulatory compliance and chain of custody. Our trucks operate as mobile cold rooms, supporting temperature controlled environments from ambient conditions to ultra low and cryogenic temperatures reaching -196°C. Our team has extensive experience managing the planning, transport, and delivery of ULT freezers, laboratory refrigerators, and liquid nitrogen storage systems. In addition to relocation services, BioRelo operates a secure biorepository facility offering both short term and long term storage solutions for biological samples, research materials, and clinical specimens.
BioNTech
As a global biotechnology company, our fully integrated business model includes basic scientific research, translational drug discovery, clinical development, GMP (Good Manufacturing Practices) compliant manufacturing and commercialization. With our patient-centered treatment approaches, we aim to become a leading biotechnology company in the fields of oncology and infectious diseases.
BioMetas
Based in Shanghai with a presence in Boston, Massachusetts, BioMetas leverages decades of expertise to provide robust biological assays for pharmaceutical and biotech companies. With a strong foundation in CRO and early-discovery services, our customer-first approach ensures high-quality data delivered with rapid turnaround times. Through our validated in vitro and in vivo biological assays, we support the advancement of therapies that advance your discovery programs forward. BioMetas is dedicated to supporting your project team, saving you time to focus on discovering therapeutic agents that benefit patient communities.